Sofosbuvir for Hepatitis E Viral Infection Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis E viral infection, particularly in immunocompromised patients and those with chronic hepatitis, have limited efficacy and safety concerns, with ribavirin showing variable success and potential failures, necessitating safer and more effective therapeutic options.
Innovation Solution
Administration of a therapeutically effective amount of the compound of Formula (IA), potentially concomitantly with ribavirin, to reduce HEV RNA levels in subjects, offering additive or over-additive effects in lowering viral loads, and suitable for immunocompromised and pregnant individuals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ribavirin is administered to treat HEV infection, then viral clearance is achieved in up to 78% of patients, but treatment failure occurs and safety concerns arise
Solution Approach 1:
The patent segments the treatment approach by introducing a novel compound (Formula IA) that acts through a different mechanism than ribavirin. This new compound targets HEV replication independently, allowing for alternative pathways to achieve viral clearance when ribavirin fails or is contraindicated.
Solution Approach 2:
The patent changes the therapeutic parameter by using a compound with different pharmacological properties (Formula IA) compared to ribavirin. This new compound achieves viral clearance through altered mechanisms, potentially improving reliability while reducing the harmful effects associated with ribavirin monotherapy.
2Reliability
If immunosuppressive therapy is reduced to clear HEV, then viral clearance is achieved in some patients, but treatment success varies and may compromise patient immunity
Solution Approach 1:
The patent introduces Compound (Formula IA) as an intermediary therapeutic agent that mediates viral clearance without requiring reduction of immunosuppressive therapy. This allows the drug to directly target HEV replication while maintaining the patient's necessary immunosuppression status.
Solution Approach 2:
The patent changes the therapeutic approach by using a compound that achieves viral clearance through mechanisms independent of immunosuppression reduction, thereby preserving patient immune function while still achieving the desired antiviral effect.
3Ease of operation
If ribavirin monotherapy is used, then treatment is simple, but efficacy is limited and treatment failure is described
Solution Approach 1:
The patent segments the therapeutic strategy by offering Compound (Formula IA) as a distinct treatment option from ribavirin monotherapy. This new compound provides an alternative pathway to viral clearance that maintains treatment simplicity while improving reliability through different mechanisms of action.
Solution Approach 2:
The patent changes the therapeutic parameter by introducing a compound with different efficacy characteristics (Formula IA) that achieves viral clearance more reliably while maintaining the simplicity of monotherapy administration.
Data Source
AI summary
Disclosed herein are methods of treating a hepatitis E viral infection comprising administering to a human subject in need thereof a therapeutically effective amount of the compound sofosbuvir, also known as (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate. Some methods further comprise concomitantly administering ribavirin to the subject. In some methods, the treatment is ribavirin-free. In some methods, the subject is immunocompromised. In some methods, the subject is pregnant.